Our contribution to prevent Disease X.
Estimated at 770 million infections and 7 million deaths, the COVID-19 pandemic caused an economic burden of US$8 trillion, triggering the most severe global economic crisis of the last century and sending shockwaves through societies worldwide. The virus caught many nations off-guard, revealing significant gaps in preparedness and response capabilities. New outbreaks will hit us 3 times more in the future than 40 years ago.
These traits are responsible for causing the next pandemic.
Enhanced global preparedness, surveillance, and continued research into vaccines and treatments are essential to manage threats effectively. The World Health Organization (WHO) has listed six viral families exhibit the traits to cause the next pandemic.
By leveraging its scalable platform, new/era/mabs can efficiently develop new tools to combat emerging infectious threats. This fast and adaptable approach enables the rapid discovery and production of virus-specific antibodies, positioning the company to respond swiftly to evolving pandemics and contribute effectively to global preparedness efforts.
Passive immunization offers immediate protection against viral threats by providing ready-made antibodies to individuals. Unlike active immunization, which requires time for the immune system to develop a response, passive immunization delivers instant immunity. This is particularly crucial during outbreaks or exposure to highly contagious viruses, as it can rapidly neutralize pathogens, reduce disease severity, and prevent infection. Additionally, passive immunization is invaluable for individuals with weakened immune systems who may not respond adequately to vaccines.
Overall, it is a vital tool in the fight against emerging viral threats, providing quick and effective protection.